Cargando…
The current status of immunobased therapies for metastatic renal-cell carcinoma
The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent time...
Autores principales: | Sathianathen, Niranjan J, Krishna, Suprita, Anderson, J Kyle, Weight, Christopher J, Gupta, Shilpa, Konety, Badrinath R, Griffith, Thomas S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723125/ https://www.ncbi.nlm.nih.gov/pubmed/29255699 http://dx.doi.org/10.2147/ITT.S134850 |
Ejemplares similares
-
Increased Surgical Complications in Smokers Undergoing Radical Cystectomy(1)
por: Sathianathen, Niranjan J., et al.
Publicado: (2018) -
Urinary Biomarkers in the Evaluation of Primary Hematuria: A Systematic Review and Meta-Analysis
por: Sathianathen, Niranjan J., et al.
Publicado: (2018) -
MRI/PET Imaging in elevated PSA and localized prostate cancer: a narrative review
por: Regmi, Subodh K., et al.
Publicado: (2021) -
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
por: Seow, Heng Fong, et al.
Publicado: (2016) -
Drain fluid creatinine-to-serum creatinine ratio as an initial test to detect urine leakage following cystectomy: A retrospective study
por: Regmi, Subodh Kumar, et al.
Publicado: (2021)